Soleno Therapeutics to Participate in Upcoming Conferences
REDWOOD CITY, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will participate in the following investor conferences in February and March:
Guggenheim Emerging Outlook: Biotech Summit 2026
Presentation Date: Thursday, February 12, 2026 at 11:30 AM ET
Presentation Format: Fireside Chat
Webcast:
Oppenheimer 36th Annual Healthcare Life Sciences Conference
Presentation Date: Thursday, February 26, 2026 at 10:00 AM ET
Presentation Format: Company presentation
TD Cowen 46th Annual Health Care Conference
Presentation Date: Wednesday, March 4, 2026 at 9:50 AM ET
Presentation Format: Fireside Chat
Webcast:
Replay of the Guggenheim and TD Cowen events will be available in the Investors section on the Company’s website at .
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s first commercial product, VYKAT™ XR (diazoxide choline) extended-release tablets, formerly known as DCCR, is a once-daily oral treatment for hyperphagia in adults and children 4 years of age and older with Prader-Willi syndrome and was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025. For more information, please visit .
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
